Literature DB >> 25388629

Ratio between fms-like tyrosine kinase 1 and placental growth factor in children with congenital heart disease.

Masaya Sugimoto1, Hideharu Oka, Aya Kajihama, Kouichi Nakau, Seiko Kuwata, Clara Kurishima, Hiroshi Azuma.   

Abstract

Serum levels of soluble fms-like tyrosine kinase 1 (sFlt-1), an antiangiogenic factor, and its binding protein, placental growth factor (PlGF), are altered in women with preeclampsia. Recently, the sFlt-1/PlGF ratio has been shown to predict acute coronary syndrome in adults. However, few reports have described the use of the sFlt-1/PlGF ratio for evaluating an abnormal hemodynamic load in children with congenital heart disease (CHD). The sFlt-1/PlGF ratio was determined in 20 children with atrial septal defects (ASD), 26 children with ventricular septal defects (VSD), 57 children with tetralogy of Fallot (ToF), 35 children who were Fontan candidates (Fontan), and 14 controls. The preoperative sFlt-1/PlGF ratios in the ASD, VSD, and Fontan were significantly higher than those in the controls and were significantly decreased after surgical repair in the ASD and VSD. In the ToF, the sFlt-1/PlGF ratio was highest after first-stage repair and second-highest after final-stage palliation compared with the preoperative levels. The sFlt-1/PlGF ratio was highest after first-stage repair and much lower after final-stage palliation in the Fontan. Furthermore, these ratios correlated with the degree of the ventricular volume overload and hypoxia. Our study clearly demonstrated that the sFlt-1/PlGF ratio increases with volume overload and persistent hypoxia after surgery with CHD. These findings may prove useful in the management of CHD in children.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25388629     DOI: 10.1007/s00246-014-1054-8

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  35 in total

Review 1.  Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces.

Authors:  Joanna L James; Guy S Whitley; Judith E Cartwright
Journal:  J Pathol       Date:  2010-08       Impact factor: 7.996

2.  Elevated soluble fms-like tyrosine kinase-1 levels in acute coronary occlusion.

Authors:  Navin K Kapur; Kevin S Heffernan; Adil A Yunis; Tuan A Nguyen; Mark J Aronovitz; Peter Parpos; Szuhuei Wilson; Corey K Baker; Michele L Esposito; Ameer Shah; Carey D Kimmelstiel; Andrew Weintraub; Richard H Karas; Michael E Mendelsohn
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

3.  The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Kosha Ruparel; Nancy K Sweitzer; James C Fang; Wayne C Levy; Douglas B Sawyer; Thomas P Cappola
Journal:  J Am Coll Cardiol       Date:  2011-07-19       Impact factor: 24.094

4.  Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction.

Authors:  Willibald Hochholzer; Tobias Reichlin; Claudia Stelzig; Kirsten Hochholzer; Julia Meissner; Tobias Breidthardt; Miriam Reiter; Bettina Duehsler; Heike Freidank; Katrin Winkler; Raphael Twerenbold; Christian Mueller
Journal:  Eur Heart J       Date:  2010-12-07       Impact factor: 29.983

5.  Right and left ventricular volume characteristics in children with pulmonary stenosis and intact ventricular septum.

Authors:  M Nakazawa; R A Marks; J Isabel-Jones; J M Jarmakani
Journal:  Circulation       Date:  1976-05       Impact factor: 29.690

6.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

7.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.

Authors:  D Maglione; V Guerriero; G Viglietto; P Delli-Bovi; M G Persico
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

8.  Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction.

Authors:  Kenji Onoue; Shiro Uemura; Yukiji Takeda; Satoshi Somekawa; Hajime Iwama; Taku Nishida; Yoshinobu Morikawa; Hitoshi Nakagawa; Takeshi Tsutsumi; Ji Hee Sung; Yasuhiro Takemoto; Tsunenari Soeda; Satoshi Okayama; Kenichi Ishigami; Hiroyuki Kawata; Manabu Horii; Tamio Nakajima; Yoshihiko Saito
Journal:  Am J Cardiol       Date:  2009-12-01       Impact factor: 2.778

9.  TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure.

Authors:  S Givvimani; S Kundu; N Narayanan; F Armaghan; N Qipshidze; S Pushpakumar; T P Vacek; S C Tyagi
Journal:  Arch Physiol Biochem       Date:  2013-02-11       Impact factor: 4.076

10.  Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.

Authors:  Sarosh Rana; Camille E Powe; Saira Salahuddin; Stefan Verlohren; Frank H Perschel; Richard J Levine; Kee-Hak Lim; Julia B Wenger; Ravi Thadhani; S Ananth Karumanchi
Journal:  Circulation       Date:  2012-01-18       Impact factor: 29.690

View more
  1 in total

1.  Hypothesis: human trophectoderm biopsy downregulates the expression of the placental growth factor gene.

Authors:  Angelo Tocci
Journal:  J Assist Reprod Genet       Date:  2021-08-07       Impact factor: 3.357

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.